<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04149626</url>
  </required_header>
  <id_info>
    <org_study_id>14720/29-10-2019</org_study_id>
    <nct_id>NCT04149626</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Sedation in Orthopedic Surgery</brief_title>
  <official_title>Prospective, Randomized Comparative Study of Intravenous Dexmedetomidine for Sedation in Orthopedic Surgery Under Regional Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asklepieion Voulas General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maria Tileli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chryssoula Staikou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asklepieion Voulas General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      60 patients ASA I-III, undergoing orthopedic surgery will be randomly assigned into one of
      three groups, namely group A (n=20), where dexmedetomidine will be used for sedation (initial
      bolus dose followed by continuous infusion), group B (n=20) where midazolam will be used for
      sedation (initial bolus dose followed by continuous infusion) and group C (n=20), where
      remifentanil will be used for sedation (initial bolus dose followed by continuous infusion).
      All patients will receive spinal anesthesia. Duration of postoperative analgesia, total dose
      of patient controlled IV morphine, sedation scores, nausea and vomiting, time of ambulation,
      sleep quality and patient satisfaction will be recorded for the first postoperative day.
      Additionally chronic pain on the site of surgery will be recorded in 3 and 6 months
      postoperatively.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative analgesia duration</measure>
    <time_frame>24 hours</time_frame>
    <description>Time of first demand for analgesia (PCA first bolus dose)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain: Numerical Rating Scale (NRS)</measure>
    <time_frame>24 hours</time_frame>
    <description>Numerical Rating Scale (NRS) scores (Range 0-10, 0=no pain, 10=the worse pain ever)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Doses requested, morphine consumption in mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue analgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>Paracetamol in mg consumed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation</measure>
    <time_frame>24 hours</time_frame>
    <description>Ramsay Sedation Scale (numeric score from 1 to 6, based on responsiveness of the patient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delirium occurence</measure>
    <time_frame>24 hours</time_frame>
    <description>Nu-DESK scale (presence of disorientation, inappropriate behavior, inappropriate communication,illusions/hallucinations, psychomoter retardation). Each of the 5 items is rated from 0 to 2. A total of 10 is the maximum score. A score of more than 2 identifies the presence of delirium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic pain: Graded Chronic Pain Scale (GCPS)</measure>
    <time_frame>6 months</time_frame>
    <description>Using of Graded Chronic Pain Scale (GCPS) Grade 0: No pain in prior 6 months Grade 1: Low Intensity - Low Disability Grade II: High Intensity Characteristic Pain Intensity - Low Disability Grade III: High Disability - Moderately Limiting Grade IV: High Disability - Severely Limiting</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hallux Valgus and Bunion</condition>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine sedation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam sedation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remifentanil sedation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Sedation using dexmedetomidine (initial bolus dose followed by continuous infusion)</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Sedation using midazolam (initial bolus dose followed by continuous infusion)</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Sedation using remifentanil (initial bolus dose followed by continuous infusion)</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Physical status according to American Society of Anesthesiologists (ASA) I-III Patients
        scheduled for orthopedic surgery

        Exclusion Criteria:

        Patient denial, contraindication of spinal anesthesia or any of the agents used in the
        protocol, BMI above 30, Serious psychiatric, mental and cognitive disorders, Language
        barrier, illicit substances abuse,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexandros Makris, MD, MSc, PhD</last_name>
    <phone>+306947076446</phone>
    <email>makrisalexandros@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Tileli, MD</last_name>
    <phone>+306955258090</phone>
    <email>mtileli@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asklepieion Hospital of Voula</name>
      <address>
        <city>Athens</city>
        <zip>16673</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandros Makris, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asklepieion Voulas General Hospital</investigator_affiliation>
    <investigator_full_name>Alexandros Makris</investigator_full_name>
    <investigator_title>Consultant Anesthesiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hallux Valgus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

